Entos Pharmaceuticals Announces First Participant Dosed in Clinical Trial for COVID-19 Vaccine Booster

EDMONTON, Alberta & SAN DIEGO -- Entos® Pharmaceuticals ( Entos or the Company), a clinical-stage biotechnology company developing genetic medicines with its proprietary Fusogenix™ PLV™ nucleic acid delivery platform, and its partner, Aegis Life, Inc. (Aegis), today announced the first participant has been dosed in the phase 1/2 clinical trial ( NCT06436911) evaluating Covigenix VAX-002 as a COVID-19 booster vaccine. Read More

Entos Pharmaceuticals Announces First Participant Dosed in Clinical Trial for COVID-19 Vaccine Booster

Entos Pharmaceuticals Announces First Participant Dosed in Clinical Trial for COVID-19 Vaccine Booster

Entos Pharmaceuticals Announces First Participant Dosed in Clinical Trial for COVID-19 Vaccine Booster

Entos Pharmaceuticals Announces First Participant Dosed in Clinical Trial for COVID-19 Vaccine Booster
Entos Pharmaceuticals Announces First Participant Dosed in Clinical Trial for COVID-19 Vaccine Booster
Ads Links by Easy Branches
Play online games for free at games.easybranches.com
Guest Post Services www.easybranches.com/contribute
Potential China EV tariffs welcomed by GM Canada as BYD looks to enter market